Key result
Coadministration of enalapril with ticlopidine reduced systemic vascular resistance more effectively than with aspirin (P=0.03 for time-by-treatment interaction).
Why the study?
Does ticlopidine compared to aspirin preserve the systemic vasodilatory effects of enalapril in patients with severe chronic heart failure?
Population
20 patients with severe chronic heart failure
Comparison
Ticlopidine 500 mg daily for 7 days, followed by… vs Aspirin 325 mg daily for 7 days, followed by a…
Design
RCT, allocated to, double-blind
Follow-up
4 hours post-enalapril dose (after 7 days of pretreatment)
Authors
Loading...
Ticlopidine may be preferable to aspirin with enalapril in severe HF; extends evidence on differential antiplatelet effects.
RCT (n=20)
Double-blind
Does ticlopidine compared to aspirin preserve the systemic vasodilatory effects of enalapril in patients with severe chronic heart failure?
p-value: p=0.03
Aspirin, but not ticlopidine, blunts the systemic vasodilatory effects of enalapril in patients with severe heart failure, likely due to prostaglandin synthesis inhibition.
Spaulding et al. (1998) conducted an RCT in Severe chronic heart failure (n=20). Ticlopidine vs. Aspirin (325 mg daily) was evaluated on Systemic vascular resistance (p=0.03). Coadministration of enalapril with ticlopidine reduced systemic vascular resistance more effectively than with aspirin (P=0.03 for time-by-treatment interaction).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: